title: Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren's syndrome.
authors.affiliation: Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, , Groningen, The Netherlands.
authors.forename: R P E
authors.initials: RP
authors.lastname: Pollard
authors.forename: W H
authors.initials: WH
authors.lastname: Abdulahad
authors.forename: H
authors.initials: H
authors.lastname: Bootsma
authors.forename: P M
authors.initials: PM
authors.lastname: Meiners
authors.forename: F K L
authors.initials: FK
authors.lastname: Spijkervet
authors.forename: M G
authors.initials: MG
authors.lastname: Huitema
authors.forename: J G M
authors.initials: JG
authors.lastname: Burgerhof
authors.forename: A
authors.initials: A
authors.lastname: Vissink
authors.forename: F G M
authors.initials: FG
authors.lastname: Kroese
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000276:immunology; D016207:Cytokines / Q000097:blood*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D018836:Inflammation Mediators / Q000378:metabolism*; D008212:Lymphocyte Depletion; D008297:Male; D000069283:Rituximab; D012859:Sjogren's Syndrome / Q000188:drug therapy*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D016207:Cytokines; D007155:Immunologic Factors; D018836:Inflammation Mediators; D000069283:Rituximab
keywords: B cells; Chemokines; Cytokines; Sjögren's Syndrome; Treatment